Summary
Thermo Fisher Scientific Inc. (TMO) reported a significant increase in revenues and operating income for the third quarter and first nine months of 2020 compared to the prior year. This strong performance was largely driven by increased demand for products and services related to the COVID-19 pandemic, particularly in the diagnostic and healthcare markets, as well as robust demand from the pharmaceutical and biotech sectors. The Life Sciences Solutions and Specialty Diagnostics segments showed substantial growth. Despite a challenging environment for some industrial and academic customers due to the pandemic, overall financial health remains strong. The company ended the period with a substantial cash balance and positive operating cash flow, indicating a solid liquidity position to support ongoing operations and potential future investments. Management expressed confidence in the company's ability to meet its financial obligations and requirements for the foreseeable future.
Financial Highlights
54 data points| Revenue | $8.52B |
| R&D Expenses | $296.00M |
| SG&A Expenses | $1.59B |
| Operating Expenses | $6.09B |
| Operating Income | $2.43B |
| Interest Expense | $144.00M |
| Net Income | $1.93B |
| EPS (Basic) | $4.88 |
| EPS (Diluted) | $4.84 |
| Shares Outstanding (Basic) | 396.00M |
| Shares Outstanding (Diluted) | 399.00M |
Key Highlights
- 1Total revenues for the nine months ended September 26, 2020, increased by 16% to $21.67 billion, up from $18.71 billion in the same period of 2019.
- 2Net income for the nine months ended September 26, 2020, rose to $3.88 billion from $2.69 billion in the prior year's period.
- 3Operating income for the nine months ended September 26, 2020, increased by 40% to $4.72 billion.
- 4Cash flow from operating activities was robust, totaling $4.95 billion for the first nine months of 2020, a significant increase from $3.06 billion in the same period of 2019.
- 5The Life Sciences Solutions segment saw remarkable revenue growth of 55% for the nine months ended September 26, 2020, driven by COVID-19 related testing and bioproduction demand.
- 6The company ended the period with $7.54 billion in cash and cash equivalents, a substantial increase from $2.40 billion at the end of 2019, indicating strong liquidity.
- 7The Analytical Instruments segment experienced a revenue decrease of 13% for the nine months, primarily due to weakened economic conditions related to COVID-19 affecting industrial and academic customers.